Bionomics Limited, kambani yekiriniki-nhanho biopharmaceutical kambani, yakazivisa kuti yatanga chikamu chechipiri chekuyedza kiriniki (iyo PREVAIL Chidzidzo) kuongorora BNC2 yekurapa kwakanyanya kweSocial Anxiety Disorder (SAD), ine mibairo yepamusoro inotarisirwa mukupera kwa210.
BNC210 ndeyemuromo, yevaridzi, yakasarudzika isina kunaka allosteric modulator ye α7 nicotinic acetylcholine receptor mukuvandudza kurapwa kwakanyanya kweSAD uye kurapa kusingaperi kwePost-Traumatic Stress Disorder (PTSD), neUS Food and Drug Administration (FDA) Fast Track kudomwa. kune zvese zviratidzo zvekiriniki.
The PREVAIL Study SAD protocol yakacheneswa neFDA muna Mbudzi 2021, uye yakapihwa mvumo yetsika nepakati US Institutional Review Board (IRB) muna Zvita 2021. Nemvumo iyi iripo, pamwe nemvumo yesaiti-level, nzvimbo dzekiriniki. muUS ikozvino yakavhurwa uye yakavhurika kuongororwa kune vangangove vatori vechikamu kudzidza vane makore 18 kusvika 65 makore ane yakamaka kune yakanyanya SAD. Vatori vechikamu muChidzidzo vachada kuwana zvibodzwa zvinosvika makumi manomwe paLiebowitz Social Anxiety Scale, chinova chikero chinoongorora huwandu hwemurwere hunoshumwa hwesocial phobia mumhando dzakasiyana dzemagariro nekuita. Zvinotarisirwa kuti 70 kusvika ku15 nzvimbo dzekiriniki muUS dzichabatanidzwa mukuunganidza varwere kuongororo iyi.
Mune iyi randomied, double-blind, placebo-controlled controlled trial, BNC210 ichaongororwa seyakanyanya, kana imwe-dose, kurapwa kwevarwere vane SAD. Vatori vechikamu chekudzidza vanozopihwa zvisina tsarukano kune rimwe remapoka matatu ekurapa, 225 mg BNC210, 675 mg BNC210 kana placebo, ine vangangoita makumi mashanu vatori vechikamu muboka rega rega. Vachapihwa nemuromo muyero mumwechete wekurapa kwavakapihwa ingangoita awa imwe chete vasati vatora chikamu mukuita basa rinoshungurudza rekuita rinosanganisira dambudziko rekutaura. Chinangwa chikuru chechidzidzo ndechekuenzanisa yega yega nhanho yeBNC50 kune placebo pane yekuzvizivisa-yekushushikana mazinga uchishandisa iyo Subjective Units yeDzimba Scale (SUDS). Zvinangwa zveSekondari zvinosanganisira zvimwe zvikero zviviri zvinoyera nhanho dzekushushikana kwevatori vechikamu (State-Trait Anxiety Inventory uye Kuzvitaura Panguva Yekutaura Paruzhinji), pamwe nekuongororwa kwekuchengetedza uye kushivirira kweBNC210 muhuwandu uhu.
“Matambudziko ekufunganya mutoro wakakura kunharaunda dzedu uye vanhu vakuru vangangosvika mamirioni gumi nemasere vanotambura neSocial Anxiety Disorder muUnited States chete. Varwere vanozogara vachinzwa kutya kwakanyanya uye kwakasimba kwemamiriro emagariro kana ane chekuita nekuita kana vakasangana nevanhu vasina kujaira kana kuongororwa kunogona kuitwa nevamwe. Vanowanzo pinda mumaitiro ekudzivirira kubata kutya kwavo, izvo zvinogona kukanganisa kushanda, kuwedzera kusurukirwa uye kuzviparadzanisa nevamwe, uye kuderedza hupenyu hwehupenyu. Pane kudiwa kukuru kusingakwane kwekukurumidza-kuita, se-kunodiwa kurapwa kuvarwere ava nekuti iyo chete FDA yakatenderwa mishonga yeSocial Anxiety Disorder inotora mavhiki akati wandei kana kupfuura isati yakanganisa zviratidzo. Kurapa kwakachengeteka uye kunoshanda kwevanoda kunogona kubatsira vanhu vane Social Anxiety Disorder kuti vabatane, pane kudzivirira, mamiriro ezvinhu anotsamwisa pavanenge vachida zvakanyanya. " akadaro Bionomics 'vanopa mazano kuYunivhesiti yeCalifornia (San Diego) Dr. Charles Taylor (Mubatanidzwa Purofesa, Dhipatimendi rePsychiatry) uye Murray Stein (Purofesa Akakurumbira, Dhipatimendi rePsychiatry).
"Iyo piritsi nyowani yeBNC210, iyo inokurumidza kunyudzwa uye inosvika pakunyanya kunyura muropa mukati meawa imwe chete, iri kuongororwa muchidzidzo chePREVAIL semumuromo se-inodiwa kurapwa kwevarwere veSAD kuti vararame zviri nani nezvinofungidzirwa-zvinokonzeresa magariro. kudyidzana uye mamwe marongero eruzhinji. Tinotarisira kutora mukana weiyo Fast Track mazita ezviratidzo zveSAD nePTSD, uye chinangwa chedu ndechekutaura data repamusoro mukupera kwa2022 yePREVAIL Chidzidzo uye pakati pa2023 yekuenderera mberi Phase 2b PTSD ATTUNE Chidzidzo. akadaro Sachigaro Mukuru weBionomics, Dr. Errol De Souza.
